Spirax Group plc (SPX) Earnings Call Transcript
March 10, 2026
Earnings Call Speaker Segments
Just waiting for the cue. Hello, and thank you for joining this presentation of Spirax Group's results. Nimesh Patel here, Group CEO, and with me is Louisa Burdett, our Group CFO. I'll begin by summarizing how we performed in 2025. The results we're reporting today show that we can deliver good organic growth at high margins by concentrating on the operational priorities within our control, and this held true despite the weak macroeconomic environment that persisted throughout the year. Turning to our organic measures, we outperformed IP, with group sales growth of 5%. Adjusted operating profit grew 6%, and all three businesses delivered growth and improved margins. Group margin was 20%, up 30 basis points, as we maintained pricing and cost discipline and managed the headwinds from FX and tariff impacts, while also investing in future growth. A good set of results slightly ahead of expectations. I want to thank my colleagues around the world for their commitment to achieving these results through advancing the execution of our strategy. In STS, the market trends we've been highlighting since the first half of 2024 played out as expected, with geopolitical tension and tariff volatility driving lower IP and weak demand for large projects.
China and Korea were hit especially hard, though in both of those markets the headwinds started easing during the second half, which is what we had expected. Crucially, we kept offsetting those headwinds by concentrating on MRO and solution sales, which produced 1% growth in STS and 3% growth excluding large projects in China and Korea, at a margin of 23.5%. In ETS, our operational emphasis is showing up as genuine results, with output from the North American factory climbing by more than 20% over the past two years. Through 2025, robust demand across all three ETS divisions, together with those operational improvements, has generated 11% sales growth and additional margin gains. At Watson-Marlow, we have said all along that the biopharm recovery would take a U-shape, and that is how it has played out. Demand growth above 10% in 2025 underpinned accelerating sales growth in the second half. In Process Industries, where we reorganized our sales teams so they could better serve target sectors, we generated demand growth well ahead of IP. As a result, Watson-Marlow sales rose 6% and margins increased 160 basis points to 26.2%. Back to the group-wide picture: in January last year, we carried out a significant restructuring. That work is now finished, and annualized savings are significantly ahead of our original plan of £40 million.
Those savings are what fuel our spending on future growth, which I'll cover in more detail later. On cash conversion, it rose to 89%, and leverage came down to 1.5 times, which shows our discipline around cash. Return on capital employed climbed to 36%, and return on invested capital rose to 13%, and both of those came despite significant FX headwinds. As we look forward, we expect mid-single-digit organic growth in 2026, and operating leverage should push adjusted operating profit growth above that level. In summary, compared with the targets we laid out at our capital markets event, we are squarely on track. We're getting back to the simple approach of delivering solid growth at high margins while improving returns on capital. By concentrating on what we can control, we're making ourselves more resilient to economic conditions. Let me now provide some context on the wider demand environment. The macroeconomic backdrop stayed weak and volatile throughout 2025. We navigated geopolitical shifts, trade tariffs, and regional conflicts successfully to deliver growth ahead of IP, and we'll do the same in 2026. The chart on the left shows how IP forecasts changed over the course of 2025. As a reminder, we concentrate on IP excluding China because of continuing worries about the quality and reliability of data specific to China.
The thing that stands out clearly is that global IP expectations got weaker as the year went on, and they stayed under the historical averages, which sit closer to 3%. Importantly, you're able to see how the US tariffs announced in April had an impact. The pattern mirrors forecasts from prior years: optimism at the start of the year, then actual IP coming in below what was expected. If you turn to the tables on the right-hand side, IP was still weak across our key markets, and global IP excluding China came in at 1.7%. Now, as we look toward 2026, global IP excluding China is forecast at around 2%, though that depends on a significant step-up in growth, from 1.6% in the first half to 2.5% in the second half, which isn't dissimilar to the pattern forecast for 2025. Given how much volatility we've seen over the last two years, we've once again taken a more conservative view in our internal planning assumptions. Let me briefly touch on the Middle East, which accounts for around 1% of group sales. It's too early to fully assess what the impacts will be on 2026, but we are preparing for potential supply chain disruption, which we currently expect will largely be felt in the first half. As for changing tariffs, again, the most significant effect is likely to fall on demand.
On the manufacturing side, having operations in the USA allows us to satisfy a substantial share of domestic demand right where it arises. Put simply, as 2025 showed, we possess the flexibility, the regional footprint, and the pricing discipline needed to respond effectively. The IP outlook, shifting tariffs, and geopolitical risk each underscore how important it is that we can self-generate demand. That point deserves emphasis. Through our direct sales model — with a focus on more customer-facing time, sector specialization, and disciplined pricing — we keep generating high-quality demand from our sizable installed base. Entering 2026, we have planned cautiously, yet we remain confident in our capacity to keep outperforming IP, exactly as we have done consistently for decades. I'll now pass things to Louisa, who will walk you through the year's financial performance before I update you on our strategic progress.
Hi, everyone. Let me begin with the usual brief reminders regarding my presentation. The figures I'll be walking through are on an adjusted basis, leaving out amortization of acquired intangibles, and in particular leaving out the £40 million cost of our restructuring project, which we undertook this year. You'll find the reconciliation between statutory and adjusted operating profit in the appendix of your pack. As always, when we talk about organic growth, we exclude the effect of currency movements on sales and profit as well as the impact of any M&A. Currency movements this year had a negative 3% effect on sales and a negative 4% effect on operating profit. Nimesh has already covered some of the group numbers in his introduction, so I'll keep my comments on this slide brief. Sales came in 5% ahead — sorry, I beg your pardon — sales were 5% higher organically, ahead of IP, and driven by growth in each of the three businesses, but particularly by ETS and Watson-Marlow. Operating profit was up 6%, and operating margin of 20% was 30 bps higher organically. Our net financing costs of £38 million came in below the prior year, thanks to lower average net debt, lower rates on the floating element of our debt book, and the positive impact of our cash centralization initiatives.
As we anticipated, the effective tax rate rose to 27.3%, driven by the mix of profits and a few one-off benefits in the previous year. Adjusted EPS came in at 296.3 pence per share, up 3%, and the full-year dividend of 170 pence per share includes a 3% rise in the final dividend, which reflects our ongoing confidence in getting back to stronger growth and margin levels. Moving to the sales bridge, organic sales growth for the group beat IP, reaching 5%, while currency movements had a negative effect of £37 million, or 3%. In Steam, organic sales growth for the full year was 1%. After holding broadly flat in the first half, the business grew 2% in the second half, led by MRO and solution sales, with weakness in large projects in China and Korea moderating. As Nimesh has already mentioned, if we strip out those large projects in China and Korea, the rest of Steam grew 3%. In ETS, organic sales growth for the full year was 11%, with a second-half figure of 12% against a strong comparator. That reflects operational improvements and new business wins in Process Heating, along with continued strength in Semicon. Watson-Marlow grew 6% organically. As expected, our biopharm sales growth sped up to high single digits in the second half, and Process Industries kept performing strongly.
Within Process Industries, the second-half increase was due to the scheduling of a particular medical order in that period, something we flagged when reporting half-year results. Yet even after making an allowance for that, the growth achieved in Process Industries comfortably exceeded IP. Moving to the operating bridge, all three businesses posted better margins, while currency effects subtracted £14 million, equivalent to 4%. Organic operating profit for Steam rose 3%, outpacing sales growth, helped by manufacturing efficiencies together with a modest amount of net savings stemming from the restructuring program. Consequently, Steam's operating margin of 23.5% was 40 bps better on an organic basis. At ETS, organic operating profit climbed 12%, supported by greater volume and ongoing efficiency gains in Process Heating, and the operating margin improved 20 bps organically, reaching 16.2%. It was encouraging to observe margin improvement year on year at ETS, though, as we pointed out at interim results, the scale of that improvement relative to robust sales growth was tempered by delivery of the legacy orders at Ogden, which had not been repriced for inflation, along with certain initial costs tied to starting up the new medium-voltage facility. Even so, the ETS margin rose steadily through the year, with a stronger margin in the second half.
At Watson-Marlow, organic profit grew 13%, and the margin improved 160 bps to 26.2%. Beyond volume, manufacturing efficiencies helped drive our trading margin improvement. Corporate expenses are still roughly 2% of group sales; the year-on-year rise reflects investments supporting key strategic initiatives in digital and decarbonization. On cash flow, operating profit to cash conversion increased to 89%, helped by the growth in operating profit, while disciplined capital expenditure at 4% of sales offset a working capital outflow. That working capital outflow mainly reflects higher receivables, given the strong sales performance late in the year. Our working capital to sales ratio improved slightly versus the prior year, by 10 bps, aided by some new supplier terms negotiated in 2025. As you can see, we closed the year with net debt of £564.7 million, equal to 1.5 times EBITDA, and we comfortably satisfy all covenants under our external debt facilities. Nimesh and I have already noted the £40 million cost of our restructuring project, which was charged to the statutory P&L. Of that, £7 million consisted of non-cash charges, and out of the remaining £33 million, we spent £22 million in cash during 2025, with the £11 million balance largely to be spent in 2026.
This restructuring program is going to produce £40 million in annualized savings. Roughly 50% of those savings had already been achieved in 2025, and Nimesh will walk through a few examples afterward of how we've plowed that money back into sales capability and headcount, digital capability, new product development, system development, and our decarbonization opportunities. Now that I've taken you through the main points from our 2025 results, I want to move to group guidance for 2026, shown on the left-hand side of this chart, and then tie that back to the medium-term financial targets we laid out at the capital markets day in October '24, which appear on the right-hand side. Beginning on the left with the 2026 guidance: we expect Steam to keep growing faster than IP outside China, and we look for continued improvement in the trend rate for large orders in China, so we're guiding to low-single-digit organic sales growth, along with a modest organic gain in the Steam margin. Within ETS, we expect the robust order book in Process Heating, plus momentum in Semicon, to underpin high-single-digit organic sales growth. Shipping the legacy orders at Ogden takes away a major headwind that held back margin progress in 2025, and we now expect strong margin progress in 2026, helped by operating leverage and a favorable impact from the larger share of Semicon sales.
For Watson-Marlow, we're expecting organic sales growth in the high single digits, fueled by continued expansion in biopharm demand, and Process Industries should once again outperform IP. We expect operating leverage at Watson-Marlow to underpin another solid year of organic margin improvement, with a bps gain broadly comparable to what was achieved in 2025. Corporate costs are set to come in somewhat above 2025 levels, reflecting investment in future growth areas like digital services and Decarb — but setting those investments aside, the rest of the corporate costs needed to support our PLC stay firmly under control. For the group overall in 2026, that translates into mid-single-digit organic sales growth and a further rise in group adjusted operating profit margin, with adjusted operating profit expanding faster than sales. You'll find some additional group guidance factors in the appendix of your pack. So then, to wrap up from my side, I'd like to shift focus on that same slide toward the middle and right-hand side of the chart, covering the medium-term targets. Over the course of 2025, we've put in place the foundations behind our confidence that organic group margin progression will speed up across the coming few years, starting from the 20% baseline we delivered in 2025. I'll cover four of these items. First off, operating leverage.
With Watson-Marlow, we've managed to meet the pickup in biopharm sales during the second half, thanks to a business that has been well invested. As biopharm moves through its growth cycle, volume leverage is going to be an essential piece of getting our margin moving upward again toward the 30%-plus historic levels this business has delivered over the medium term. Second, the operating improvement at ETS. We've dealt with the legacy orders in Process Heating, and we're still working through other internal operating barriers that until now have held back throughput and margin — design engineer lead times being one example. Our teams are responding really well to underlying demand in resistance heating and to the Semicon demand recovery, and all of this is starting to be reflected in the second-half '25 exit margin, which, along with pricing opportunities, helps us to see the path to a 20% margin for ETS. Third, growth investment. As we've highlighted, we are delivering £40 million of annualized savings from our restructuring program. We will invest most of this back into the business, and whilst this is not immediately accretive to margin in-year, these investments will underpin future growth and returns, particularly on the commercial and digital side. Finally, continuous improvement. It's becoming business as usual at Spirax to seek out procurement savings and other continuous improvement opportunities to help us to offset inevitable negative margin factors that we can't control.
To sum things up overall, we remain on course to hit the group's medium-term margin goal of 22% to 23%, and that should push return on invested capital above 15%. We're eager to keep bringing you updates on our medium-term progress going forward, but at this point, Nimesh, I'll turn things back over to you.
Thanks, Louisa. Now let's look at a few of the main factors behind how we performed in 2025 and how we're carrying out our Together for Growth strategy. Before this, I went through the macroeconomic environment we encountered in 2025. What I want to do on this slide is hone in on the particular end-market dynamics and the way those influenced our results. First, consider STS and large project demand in China. Roughly 15% of STS sales came from China, and that market has felt the impact of slower customer capital investment in expanding manufacturing capacity. Compared with other regions, China has historically had greater exposure to large projects. Even so, as we anticipated, the drop in large project demand eased as 2025 went on, improving sequentially from the first half into the second half. The point I really want to emphasize is how well our emphasis on MRO and solution selling has continued to pay off in China. Our deep process knowledge matters greatly in this area, and it helps us generate double-digit growth across a substantial installed base. With large project trends easing and MRO growing, China sales for 2025 declined 3%, versus a 13% decline in 2024. Going forward, we anticipate capital project demand in China will level off and then rise, so that, together with our ongoing MRO progress, we can see a route for China to get back to growth sometime late this year or in 2027.
Turning now to ETS and Semicon — and just to remind everyone, even though this is only 3% of group sales, it's a high-margin area for us because our products serve highly bespoke applications. Over the course of the year, we observed an encouraging pickup in Semicon demand. It isn't a return to the 2022 peaks, but it represents a meaningful recovery, with growth in the double digits. Lastly, biopharm, which accounts for 50% of Watson-Marlow, recorded an orders increase of more than 10%. In the first half, and for the first time since peak COVID demand in 2021, orders came in above sales. That underpinned stronger second-half sales and gave us our first year of biopharm sales growth since 2022. The underlying biopharm drivers are still robust. End-user demand keeps growing strongly, and we also saw recovery among OEMs, which had been more volatile previously. Given the economic backdrop I described earlier and these shifting market dynamics, we are adapting, and our teams have shown the power of focusing on the controllables. When I say controlling the controllables, what do I mean? We're identifying opportunities to both drive organic growth and deliver higher margins regardless of economic conditions. For instance, in January 2025, we launched a series of changes aimed at improving organizational fitness. Those changes have helped us become more agile, scalable, and customer-focused.
On top of that, our operational excellence efforts helped us spot ways to streamline the manufacturing footprint and boost throughput with no extra capital — which brought our overdue backlog down and let us keep up with rising demand. Those moves have also let us concentrate more sharply on commercial excellence, producing growth that outpaces the market. Alongside that, we've changed the way we collaborate with channel partners, how we go after new sectors, and how we build new solutions that address what customers are struggling with. I'll walk you through a few examples on the coming slides. Our restructuring program, which Louisa described, grew out of both organizational fitness and operational excellence, and it delivers £40 million in annualized savings — I'll show you some instances of how we put those savings back to work. To illustrate how organizational fitness underpins growth above IP and builds a sturdier base for the next stage of sustainable growth, I'll begin with STS EMEA. Over the course of 2025, we cut the count of operating companies in EMEA by nearly 50% while still serving the same 23 countries and safeguarding our direct local sales force. We took out management layers, grew the ranks of customer-facing sales engineers, and brought technical sales and service capability together so it could be better leveraged across our operating companies. The payoff is already visible in stronger customer engagement and solution selling, with organic sales growth speeding up to 3% in the second half — comfortably ahead of IP at 1%.
One factor behind ETS growth in 2025 was setting up Heat Trace as a division with its own dedicated sales engineering team, focused on new sectors, regions, and customers. By spotting untapped opportunities, we're turning Heat Trace into a real growth engine, delivering double-digit demand and sales growth in this attractive-margin part of ETS. Last, on Watson-Marlow, we reorganized our direct sales teams in EMEA around target sectors, which lets us deploy our deep expertise more effectively straight into customers' processes and build even deeper relationships. This is working exactly as intended. We achieved double-digit demand growth in the region, with an especially strong second-half performance and Process Industries growing well above IP. In fact, Process Industries across all regions through our sectorized focus keeps performing well ahead of IP, with double-digit demand growth in target sectors. On operational excellence, this is an area where we've continued to make meaningful progress improving efficiency across the group, driving better margins while navigating trade tariffs and meeting growing demand. In STS, we closed our facility in Mexico, moving production to the USA. After deciding to pause the planned expansion of our Gestra facility in Germany, we reached agreement with the works council on how to drive meaningful efficiency and performance improvements.
Within Watson-Marlow, we shut down the Alitea pump site in Sweden, which carried higher costs, and moved that production into the UK. On top of that, we kept shifting manufacturing into our USA facility so we could meet the requirements of the Build America, Buy America Act, and that pushed volumes up by more than 20%. Over in ETS, we brought production together in the USA and closed one site. The big standout was the operational gain in Process Heating across North America, where, as I mentioned, output from our factories has risen by over 20% during the past two years, and customer lead times have come down substantially. Our expansion of the dedicated medium-voltage facility in Ogden is now finished — on time and within budget — and production there is starting to ramp up. Across both ETS and Watson-Marlow, responding quickly to growing demand has let us serve customers well, which in turn makes those long-term relationships stronger. Last, on our group-wide push for continuous improvement, we achieved procurement savings in the high-single-digit millions, which helped protect our margin. Now let me share a few examples of how we've sharpened our focus on commercial excellence, beginning with STS in the USA. We took a fresh look at how we work with distributors in the USA — they account for roughly 70% of local sales — by approaching it differently.
We’re partnering to co-generate demand from end users so we can speed up growth, and that means defining joint go-to-market strategies in sectors and with customers we target together. In 2025, we put this approach in place with 22 distribution partners, which drove a high-single-digit rise in demand from those onboarded earlier in the year. That shows how we can adjust to local market structures while drawing on the strength of our direct sales approach to pinpoint solutions to customer problems and generate higher growth ourselves. At present, roughly 50% of USA sales are either direct or co-generated. Turning to ETS, we’ve made solid progress expanding into new end markets. As an example, we achieved strong growth by going after the data center sector with temperature control solutions across both Process Heating and Heat Trace. That clearly demonstrates our business model working in ETS: spotting a customer need, applying our applied and design engineering expertise to put forward a solution in a new market, and delivering consistently. This focus produced a material contract win that supported ETS growth in 2025. We invested further in Watson-Marlow Architect, our proprietary single-use assembly solution for connecting disparate OEM systems across the bioprocessing fluid pathway. Added sales headcount and expansion into new regions drove demand growth of more than 30% and materially increased our opportunity pipeline, particularly in the USA.
Group-wide, clarity, accountability, and how quickly we execute our strategy have all gotten better. That's helping us match talent and investment to the largest growth opportunities, and it's already producing measurable commercial impact. Our operational priorities free up capacity for investing in future growth—for example, by building out our digital and services capabilities. We're also building customer partnerships. Because we're more connected with customers, we walk the data as well as walk the plant, which helps us anticipate what they need, solve their problems faster and better, and share in the value we find through our pricing. This approach is driving growth in MRO and solution sales. In STS, we more than doubled paid-for customer connections, to over 2,000 sites. Our targeted digital value propositions—wireless steam trap monitoring in particular—delivered high-double-digit growth in digital product and service revenues, plus additional strong product pull-through from optimization and replacement opportunities. We've also made progress developing our secure and scalable Connect platform, which gives customers access to real-time data, operational insights, predictive analytics, and sustainability metrics. This digital innovation is benefiting Watson-Marlow and ETS as well. With our Connect-enabled Pump Insights pilot in Watson-Marlow, we've moved a mining sector customer away from reactive fixes and costly unplanned downtime toward proactive pump management in abrasive high-density slurry applications.
To wrap up, we're continuing to expand MIM — our large language model — which has now been deployed to more than 1,000 sales colleagues, roughly one-third of the total, and the earliest users are freeing up about four hours each per week, time that's being redirected toward additional customer-facing activities. On the right-hand side of this slide, we lay out where we've been investing when it comes to decarbonizing thermal energy. There are four defined go-to-market strategies, as shown on the slide, and across STS and ETS we're bringing together our unique expertise in steam, heat transfer, and electric resistance heating to deliver integrated solutions that are generating multi-year growth opportunities, especially as customers look to modernize and decarbonize aging thermal infrastructure. A few examples from last year. First, we designed and supplied medium-voltage heaters for renewables energy storage, along with low-voltage heaters to replace highly carbon-intensive gas heaters in tissue production. Second, we delivered a multi-site thermal energy assessment for a major food and beverage customer, in which our cross-functional team identified annual energy savings of around 10%, along with an associated pull-through revenue opportunity for us of over £1 million. We're demonstrating our unique customer value proposition and delivery model. All told, through our progress in digital customer connections, MIM, and our decarbonization solutions, we're advancing the long-term growth potential of our group.
That was 2025. Now let me give you some context on how we're building on our strengths to deliver over the medium term and beyond. Some of this will be familiar to you. Starting on the left, we have a unique and powerful business model that underpins three strong growth engines and their durable competitive advantage. That's what has made it possible to deliver consistent organic growth ahead of IP over many years and through multiple economic cycles. In the center of this slide, you see we have significant runway to keep delivering high-margin, high-return organic growth in a very large addressable market. We're well-positioned to capture this through our Together for Growth strategy: one, by focusing on the operational priorities I've been explaining, we will deliver on our medium-term targets and generate the funding to invest in growth; and two, through targeted investments that enable us to capture the significant opportunities we see ahead, we will accelerate the rate of organic growth in the long term and generate attractive returns. Then on the right-hand side, you can see how our strategy translates into financial ambition. You're familiar with our sales, margin, and cash targets. Delivery on these targets will drive an improvement in ROIC to over 15%, as many of you have already anticipated and as Louisa described earlier.
Today we're confirming a leverage target range of one times to 1.5 times. We began with our business model and walked through how our strategy builds on it to hit our financial targets; the next key piece is how we think about capital allocation so we can drive long-duration, resilient compounding earnings growth — and, in turn, attractive shareholder returns. You'll know the various versions of this model; what I want to point out is how it maps specifically onto Spirax. First, we're a high-margin business with low capital intensity and a history of strong returns on capital employed, which sit at 36% right now and are rising. We'll keep investing in our own operations to strengthen our competitive position in target markets, boosting profitable organic growth and that high ROCE. I've shown you today some examples of where we've put money to work. Second, we're a high-cash-conversion business at 89%, and that has underpinned a 58-year record of dividend growth, which we'll carry on, with cover improving to two to 2.5 times. Third, we'll keep a resilient balance sheet, and I've shared our leverage target with you. Once those priorities are met, we'll take a risk- and opportunity-adjusted approach to deploying surplus capital, to further lift earnings growth and return on invested capital.
That covers bolt-on acquisitions as well as returning capital to shareholders. Regarding M&A, let me be clear about our thinking on acquisitions going forward. They would be bolt-ons rather than building a fourth leg, ones that deliver growth or margin enhancement opportunities in our core markets, where we can plainly see how to achieve better performance through our direct sales business model and/or by improving the solutions we provide to customers and capturing that value via pricing. For the right acquisition, we are comfortable with temporarily elevated leverage, though we are committed to returning it to our targeted range within a reasonable period. We understand that what matters is shareholder return, and for any acquisition we will always evaluate both the impact on ROIC and the impact on earnings growth, and we will benchmark this against a return of capital to shareholders. That is how we structure our approach to delivering compounding growth and therefore attractive returns to shareholders. To summarize before we move to Q&A, we delivered on the expectations we set out at the beginning of the year against the backdrop of a volatile external environment, which is continuing. We remained focused on executing against our operational priorities, successfully delivering our restructuring, which has strengthened our efficiency and effectiveness, and is helping to fund investment in growth.
We remain on schedule to hit the medium-term targets we laid out at our capital markets event, which underpin the long-term compounding growth that our business model and strategy are going to deliver. Thank you. We're glad to take your questions now. Go ahead, Andy. I'll start with you. Good morning to you both. Thanks for the presentation. Three questions, please, standard. ETS: could you help us get our heads around what the base margin for this division is now? Perhaps you could give us the margin excluding the legacy contracts, or tell us what those legacy contract margins were? We're just trying to work out where our base sits. How much longer do the other margin tailwinds that you mentioned, Louisa, in your presentation have to run? China and STS: it looks to me like you're still on track for the declining OE to slow down and the aftermarket MRO to kind of catch up and get back into neutral territory by the back end of this year. Is that still fair? Then the last one is on the additional £40 million of investment in growth. If we were to look forward and you can pick a time period, let's call it five years, how much additional growth do you think that will have delivered relative to a base case of investing nothing?
So how are you actually keeping track of this? It seems a big chunk of the spending is landing in central costs instead of the divisions — or are you splitting it across them? I'm just trying to get a handle on how you monitor that growth. Thanks a lot. Louisa, do you want to take the first question, on ETS margins?
Sure. As I mentioned, we're genuinely happy that the team has been able to get those legacy contracts completed, and I've stated that our confidence in reaching that 20% is solid. It won't move in a straight line across the coming two years. We'll do more in '27 than in '26, but we're glad to be discussing today that strong margin improvement for '26. Look, I think you likely realize, since you've tracked this for quite a few years, that a lot is still happening in ETS, and there are several items that we believe—and that you need to believe—in order to get us to 20%. We have positive volume demand. We have legacy project orders that we've pushed through. We still have some operational improvements we're working on. Semicon demand is returning, and pricing, which is kind of at the tail end of this. Andy, not all of those items are running at a 20% rate yet. Look, the recovery of the legacy margin piece is entirely within that mix. We won't disclose that specific figure, but those are the five items you need to believe. Of the two we're still working on, operational improvements and pricing arrive later in the cycle, because you have to be good to get the price.
Thank you. Andy, regarding your second question about China: as I said earlier, the headwinds we were dealing with on large projects are moderating. Forecasting that is really difficult, but when you pair it with the strong growth we keep seeing in MRO — where confidence is high since it sits within our control — my expectation is that China overall will reach a sort of neutral territory either in the second half of 2026 or during 2027. Naturally, more recent developments, whether tariffs shifting or conflict in the Middle East, affect business confidence and could have some impact on that. Then on your last point about how our investments in future growth will pay off for us — well, in a second I'll let Louisa speak to the investments we're carrying in corporate costs, why we're making them, and how we plan to see that play out going forward. Basically, in our medium-term guidance we said we expected the group to deliver mid-single-digit growth, and last year we were at 4%, this year we're at 5% organic growth — we're in that area. We also said that over the longer term, we believe this group can do better than that.
These investments are what will fuel that expansion at an elevated pace, and so at a larger multiple of worldwide IP growth. Louisa, would you like to say something about corporate costs?
Absolutely — just to touch on the tracking point quickly. Each of our businesses has some kind of value proposition underpinning these investments; Nimesh has discussed the push behind the distribution strategy in the US. We plan on that basis, so we can genuinely see where they intend to place investment in headcount and what we expect to gain from it, and that has simply been part of our reviews. Regarding central costs, we've used the word "incubate" — specifically for some of the digital infrastructure we're building, we'll hold a bit more of it centrally, and then as the commercial side comes through, especially in Watson-Marlow and Steam, we will recharge those costs along the way.
Thanks, Jonathan.
Morning, hi. Jonathan here from Barclays. I've got three questions as well, please. First, going back to ETS and the volume growth — 11% organic in '25, if I'm right in saying that. Could you break out how much of that was basically driven by improved execution at those North American facilities? And what kind of contribution to growth should we expect from that in '26? That's the first one. The second is on Steam. You're guiding to low single digit organic growth. Is any of that volume, or is it price? Could you give us a split of how you see those dynamics playing out for that business in '26? Then the third and final one is on Watson-Marlow. You're saying the business is well-capitalized, and obviously you're adding headcount, I think, into that business in '25. Is that finished now? The question is essentially, do we get back to those really strong levels of operational gearing for Watson-Marlow in '26? Thanks.
Louisa, could you handle the ETS question? I’ll field the STS one, and after that you can take the Watson-Marlow question.
Absolutely.
Alright.
Regarding that 11% organic sales growth in ETS and how execution fed into it, we've attempted to give you some sense of how much that contribution matters through the throughput metrics we provided for the North American footprint, which is up 20% versus the prior year. Really encouraging progress there, and we anticipate seeing further gains in '26, though that might serve as a proxy, Jonathan, for some triangulation. On well-capped Watson-Marlow, look, we're genuinely thrilled to have delivered 160 bps this year, and we're indicating a comparable bps figure next year. It's firmly on track to return to 30%-plus over the medium term. That's a performance that's not insignificant. As I mentioned in my presentation, if we keep achieving that high-single, double-digit growth in Watson-Marlow, the drop-through will materialize. Just to remind you, we have some footprint in North America in Devens, and we're sort of considering shifting volume from our UK facilities, which have served us very well through some volatile tariff territory, but getting that volume through both of those factories is a critical part of '26. We're on track to reach that 30% in the medium term.
I wanted to jump in and build on the answer regarding ETS growth. What I think you're really driving at is the question of how robust underlying demand growth is. In all three divisions within ETS, underlying demand growth was very strong. In Equipment Heating, we've already discussed the Semicon contribution, which saw double-digit growth. In Heat Trace, once again, growth was very strong. I touched on that somewhat when I described the emphasis we've placed on establishing it as a new division with a dedicated sales force. Naturally, neither of those two areas was dealing with the legacy contract problem. That issue belongs to Process Heating. In Process Heating, once again, demand growth was very strong, partly because of this large data center contract, but even excluding the large data center contract, growth was still above mid-single digit, alright? Demand growth in ETS is not something we're worried about here, so the challenge for us was ensuring that operationally we can raise output to meet our customers' needs. Then your third question concerned Steam, specifically the volume versus price split.
Since we don’t break out volume versus price, what I can tell you is that, as a general rule—and this is a reasonably safe assumption—our pricing usually runs in line with inflation or only marginally above it; I mean roughly 10 or 20 basis points. If you form your own inflation estimate, you can work out how much of the effect is coming from price. There’s one more thing I’d like to leave you with, and I think it matters more: in our business, focusing on volume versus price can occasionally be somewhat misleading. Why? Because of how we sell solutions and price for value. Take Customer A, who has five failed steam traps: I might bill those traps at £300 apiece, £1,500, right? That should be a typical invoice size for us in MRO, more or less. Now suppose I visit another customer, Customer B, and they’re facing a steam delivery issue affecting a critical process, they can’t quite pinpoint it, and it’s costing them heavily through failed batches or reduced throughput; our engineers resolve those problems, and the value we’ve delivered to them is £10,000, so we might charge them £5,000—but you know what, it could still just be five steam traps.
That value shows up in price rather than volume, okay? We just need to keep that in mind when we consider that split.
That’s great — thanks so much.
I’ll start with you, Lars, and then hand the mic over. Thanks, everyone. I have two questions, both about ETS. First, just to build on the data center contract point, it sounds like the follow-on progress has been quite strong. How should we think about that as we move through this year? Is it a modest additional tailwind for your growth, or does that contract actually represent a bit of a headwind? Second, going back to margins and the 20% midterm target, that implies a fairly back-end weighted improvement, I suppose. One would think the partial recovery this year and the legacy contracts rolling off would be meaningful margin tailwinds. When we consider pricing and operational excellence, which I suppose are the two main items coming in 2027, could you frame some numbers around that? How underpriced are you, I suppose, relative to competitors, so we can gauge the size of the opportunity? And on operational excellence, I think you mentioned a 20% increase in output. Where are we in that process? Where do you want that business to reach, just to understand how we get to that sizable step-up in 2027?
Thanks. Alright, let's begin with the question on ETS growth and data centers. In that sector we've made genuinely strong progress, so that everyone grasps what our products actually do. Basically, they're built to help test the cooling systems in data centers. Rather counter to what you'd typically link with data centers, namely cooling, what we do is heat them up. The reason we heat them is so the cooling systems get rigorously tested and won't fail at a critical moment, which would cause disruption to service. As you rightly point out, Lars, we landed a large contract in 2025, but alongside that we've also been building our relationships with a whole series of other data center players. Now, since our products — and I used this example — it isn't only about applied engineering, it's also about design engineering. Many of these products are bespoke for the particular OEM that provides either the cooling systems or the testing of those cooling systems. We collaborate with them through an R&D phase, and it takes a bit of time just to ensure those products get embedded and tested before we scale them up. Turning to the specific question of what all this means for 2026, in fact we keep seeing good data center demand in 2026, and I don't think it will be a headwind for 2026.
At the same time, it won't add to growth the way it did in 2025, since that large order is already secured, and I see a genuine chance past '26 to keep expanding what we do in servicing the data center sector. That's where things stand on that. Regarding your margin question, I believe what you were really asking about began with group margin, which is a sensible starting point, and there are three elements I consider when it comes to reaching our group margin target. The first is the effect of FX — one of the most frustrating aspects across the last two years has been the headwind FX has created for us. We ought to bear that in mind, though if any of us could predict FX reliably, we'd likely all be far wealthier in different careers. There are two further items we must deliver to reach our medium-term group margin target, and you pointed to both. One is ETS at 20%, and the other is Watson-Marlow at 30%. On Watson-Marlow, Louisa addressed that question earlier, but I think everyone here is confident that this is a business capable of reaching a 30% margin, and the issue is how fast we can return to that margin, which will depend on our capacity to keep driving growth.
That's really what's going to determine whether we can get Watson-Marlow back to 30%. In ETS — and Louisa mentioned this briefly earlier — there were roughly five items that were going to help us move from where we stood in 2024 to the 20% we're aiming for. First, we had to clear out the legacy orders with low margins. Done — that's behind us. Second, we had to finish the Ogden expansion and begin ramping it up. Right now it's a fixed cost, but more and more volume will flow through that plant, so that will come. Third, we needed growth in the higher-margin areas of ETS, especially Semicon, and as I've explained, we've also identified Heat Trace as another opportunity inside ETS with better margins — we're seeing Semicon recover. Not to the 2022 peak, as I said earlier, but the recovery is starting to show, and we're seeing strong growth in Heat Trace too. Then the final two items: really, we have some additional investment going into ETS — for instance, the ongoing cyber investment, IT investment, safety investment, some of that is still running — and we didn't get as much restructuring benefit in ETS.
The bulk of the restructuring benefits were in STS and Watson-Marlow, since ETS didn't carry that large a cost base. So those are the separate pieces affecting the margin. Louisa, is there anything you'd like to add?
No, I believe this may just restate what I already mentioned, but you brought up some of the tailwinds that remain, and I would simply stress again that the shift in operating procedures and how people carry out their work is likely the item requiring the longest lead time, simply to embed behaviors across both the existing footprint and the new footprint. It isn't that we aren't pleased with the progress; it simply means that repeatable performance plus is the final piece that will come through, so. Follow-up, sorry, that 20% increase in throughput you've seen in Ogden, where do you think that should reach, in your view, for it to be where you want it to be?
Yes. It isn't only Ogden — it's North America as well, since Ogden has increased quite dramatically, and we discussed this during our capital markets day in 2024. In fact, operational excellence means doing better in every location, throughout the whole group but especially within ETS. In North America, that 20% improvement has shown up. My feeling is that we are now nearing a fairly normal throughput level even though the Ogden expansion hasn't been fully brought up to capacity yet, so there is still some additional room to gain there. Louisa is right to point out that when we consider efficiency, the first step is to raise output; the second step is to consider how to achieve that with maximum efficiency, correct? You lift performance, steady the process, and after that consider how to run it more efficiently. We have now moved into that second phase, making it as efficient as we possibly can. That is going to strengthen the drop-throughs we begin to observe across ETS more widely. Thank you. Go next door. Thanks. Two, please. On the first question, there is obviously some degree of uncertainty in the wider macro environment right now, and it may be too soon to hold a firm view on any of it, but could you speak in broad terms about how you might see, or have previously seen, customers react during stretches of severe volatility in energy prices?
When you think in broad terms about energy efficiency solutions, electrification and that kind of thing, how long does that take, and are you seeing anything right now? On the second question, capital allocation, you've indicated that at the top end of the range you're comfortable exceeding 1.5 times for the right opportunity. May I ask about the bottom end of that range, and how confident are you that the balance sheet could be optimally structured beneath that bottom end? Put another way, how proactive might you choose to be when it comes to buybacks and similar moves? Thanks. That's a genuinely interesting question regarding how customers respond to higher energy prices, and you're correct, we've witnessed it previously, notably after the conflict in Ukraine began. What we generally tend to observe, and this is one of our business's strengths, is that since we're able to help customers become more energy-efficient, we do tend to see that demand for our solutions step up. That's why our direct sales force in particular — with their deep process understanding, their local relationships and their capacity to walk the plant — matters so much. Then, of course, you combine that with our digital solutions, especially steam trap monitoring, which is where significant energy loss can occur, whether through heat being vented as steam or latent energy in waste condensate not being recycled.
We’ve got ways to address every one of those issues. We fully expect that when energy prices jump, everyone begins asking, all right, what can I do to become a bit more efficient? Since our approach is that we’ll identify the solution for you, we’ll measure the benefit, and then we’ll set the price based on payback — in effect, it turns into an easy yes for the customer: okay, that’s something I want to do. The sooner in the year you act, the greater your odds of achieving payback inside the year. That is clearly an opportunity for us. Naturally, there’s another side to it: when energy prices are elevated, businesses begin concentrating somewhat more on preserving capital, so the project portion of the business contracts a little — but keep in mind, 85% of our business comes from customers’ opex budgets, right, whether from the MRO or the solution sales I’ve been discussing. That is clearly a significant positive for us. In fact, maybe I’ll use this moment to say a little about the wider situation in the Middle East and how it might or might not affect our business. As I mentioned earlier, roughly 1% of our sales come directly from the Middle East.
The overall global IP picture and the demand level we're seeing are probably where the effect will be felt most. Relative to the current IP forecasts, we've adopted a cautious stance — whether that proves adequate, only time will tell. One operational consequence of what's going on in the Middle East, I'd say, concerns supply chain and the disruption to it. We've already sprung into action to ensure we mitigate as far as possible how that might affect our business, whether by securing raw materials or critical components, or by making sure our local sales companies hold enough stock to satisfy our customers' needs. Bear in mind that our regional manufacturing strategy is a real help to us on that front. On the cost inflation effects of the conflict, I think you're all aware that passing cost inflation back to customers and protecting our margin is something we do very well. Our track record of doing all of these things is a long one. That's just to address that point while we were on the global picture. Then, on your question about the lower end of the leverage range, Louisa, I'll come to you in a second, but I just want to say that, for me, the important thing is that historically we haven't had that lower end of the range, and in fact, in the past, particularly before the transactions around 2022, our leverage sat well below one times.
My view is that one times serves as the signal for us to begin making some of those calls you laid out—precisely those calls. Louisa, is there anything you'd like to add?
No — really, I'd just be restating what Nimesh said: naturally, at that lower end of the range, we'd be weighing it if there weren't another use for the capital. The range we put in today is one where we don't believe we're constrained on the balance sheet, and clearly we've signaled that we'd go above it for the right kind of acquisitions.
Thanks. Just head over that way a bit.
Thanks. This is Mark from Citi. Going back to acquisitions: when we consider which divisions might receive the capital, clearly the ETS division is comparatively newer, though it has faced some difficulties with expansion and projects and so on. Is that the division where you see yourselves adding bolt-ons, and given the challenges you've had over the last couple of years, is it more or less ready to do that?
Right now, I don't believe it's ready, since there's a great deal for us to accomplish in the ETS business, and over the last two years we've been working hard to bring it to the point it needs to reach. My sense is that it would divert management's attention. The real difficulty, naturally, lies with potential bolt-on deals — we have to achieve the return. At present, we're focused on realizing the return from acquisitions made previously, but whenever we complete new acquisitions, the return has to be achieved. Achieving that return isn't possible without management focus to truly drive the integration and then the acceleration of those businesses we buy. We'll be selecting businesses where we intend to speed up growth by leveraging our direct sales business model, we intend to enhance solutions, we'll intend to enhance margins — that's how the growth will come. Looking further ahead, I can see opportunities arising in all three of our businesses. What we'll do, together with our colleagues in the business, is stay disciplined in how we consider those opportunities, ensuring we identify the most attractive ones either for each of our businesses or within each of them — again, to ensure we generate those attractive returns.
When you look at it regionally, I think people would say that China isn't growing as quickly as it was a few years back, while the US is probably growing faster in a structural sense. Should that be how we think about where you're focusing geographically, or is it still too soon to tell which regions look most attractive to you?
Both are large businesses for us, but as I stand here today, considering how things are moving over the near term — and by that I mean 1 to 2 years — the US looks to me like an appealing growth market. Over a longer horizon, China remains a highly attractive market in my view, and we have a 35-year track record there of delivering strong growth at appealing margins with a very solid market position, and that economy is going to keep performing well. It isn't a question of either/or, I believe, but when it comes to how we're deploying capital, so to speak, in the near term, well, the fact is we're bringing sales engineers on board in the US to broaden our reach and back that co-generation model with our distributors, driving the growth we're able to generate by spotting the opportunities we see across our target sectors. Naturally, we aren't putting in that same amount of headcount in China. As a matter of fact, over in China we're doing retraining so we can concentrate on MRO while trimming somewhat the headcount we presently have devoted to large projects — so you can see the way we're allocating resources appropriately to make sure we capture the benefit of those near-term trends.
I appreciate that.
Thanks, Mark. Let's bring Bruno in, shall we?
Hi, this is Bruno Gjani with UBS. I wanted to ask whether you could spend a moment on Watson-Marlow biopharma orders and the way they moved across 2025, plus what you observed regarding the drivers behind that demand. When we consider the high-single-digit growth guidance for 2026, the question, I suppose, is this: what assumption about order development is baked in for 2026 for you to hit or deliver that high-single-digit organic revenue growth aspiration? Is a meaningful pickup in orders from, let's say, Q4 or H2 required, or how are you thinking about it?
Apologies — which business was that second one in?
Watson-Marlow.
Watson-Marlow,
Alright.
Apologies—I’m with you now. I’ll take a first pass, and then Louisa, please feel free to add to it, starting with the biopharm demand picture. If you think back to 2024, what began to emerge during that year’s second half was a rebound in demand from end users, which is usually the earliest signal. Keep in mind that we serve more than 4,000 end users across a fairly varied set of customers, and that level of demand tells you existing capacity is running at a higher utilization rate. You can see it in consumables pull-through and in replacements such as pumps. What we had not yet observed then was a rebound in OEM demand. Some months had been good and others bad—extremely volatile. During this year, growth with end users has kept accelerating, and OEM demand has returned too. That tells us we are not only getting consumables pull-through, but there is probably some capacity expansion happening in bioprocessing as well. That is what increases our confidence in the continuing recovery, and our view of underlying growth in the biopharm market is unchanged. As for what you need to believe to get to high single digit: essentially, remember that Watson-Marlow is 50/50 biopharm and Process Industries.
We've consistently referred to underlying biopharm growth at roughly the 10% mark, and we've also said Process Industries would outpace IP—at minimum at 2 times IP. If you work through the arithmetic yourself, you can likely arrive pretty swiftly at a high-single-digit figure from those trends.
I'd like to ask a follow-up about the data center contract and the market. You're making solid progress with the liquid cooling OEM you already work with, but how does the process of choosing other liquid cooling OEMs actually work? Is it necessary to break up an existing relationship with another party that supplies a comparable solution? How near do you believe you are to accomplishing that at this point? Any additional detail would be helpful.
So in fact, we are approaching a lot of these OEMs proactively and asking how they are thinking about testing these systems. What we often find is that they are still working through which technologies are available to them, and that everyone wants cheaper, faster, quicker ways of doing this, right — more agile approaches. Just as we did with the large contract we won in 2025, and with others, we are in there right from what I would essentially call an R&D phase. Now, this is not long-duration R&D of the kind we see, for instance, in the Semicon sector within our Equipment Heating business. Really, I would describe it as solution selling — understanding the customer's needs and the problem they are trying to solve, looking at the electric resistance heating products we have, thinking about how we can bespoke them, and sometimes it is not that complicated to do so with our design engineering capability — thinking about how we can scale up manufacturing for that large contract order we won in '25. We installed a dedicated line at our Nuevo Laredo factory in Mexico. Thinking about how we do that, and then making sure we truly deliver to their needs.
That’s the process we’re going through right now with new names.
From a mix standpoint, when it comes to delivering on those data center contracts, is there anything worth flagging? Does it leave margin neutral, or is it accretive to ETS, or something else?
Since all the business we're winning should come in above that 20% target we've set, it's accretive — but I'd add that it's also good margin business.
I'm not sure how best to put this, but with lead times falling that fast—from 60 weeks down to 6 weeks—I'd have assumed there would implicitly be some kind of mechanical pressure on your order intake, simply because customers no longer need to place orders a year ahead of time; they'll hold off. That pressure didn't show up this year. Could you talk about some of the underlying strength in orders, and whether that caught you by surprise, and just a little about what's happening? No, it's great, actually.
That's a great question. What we've observed is design engineering lead times dropping from 60 weeks down to 6 weeks. Total lead times remain longer than 6 weeks, since there are additional stages in the process you still have to work through. In Process Heating, especially with large heaters — which is the area we're discussing — for units coming out of North America, a one-year lead time, a 40 to 50-week lead time, is not uncommon. The explanation is that our products are critical to our customers' processes or their facilities, so they generally want to get ahead by ensuring the design has been completed, the design has been signed off, there are multiple steps throughout, and that they're in the queue for manufacturing, and then they want certainty they'll receive it when we say they will. That's why you haven't seen somewhat more pressure on demand. At the same time, the underlying demand for electric resistance heating and electrification products — we mentioned data centers — all of that is simply growing too, which benefits us. From a demand standpoint, we're in good shape as well.
Thanks.
Thanks, Bruno. Mel, let me just check — was there anything from the phone lines? Nothing from the phone. Any other questions here in the room? Great. Well, thank you all very much for being with us — everyone here in the room and those of you on the call. We appreciate your support, and we look forward to seeing you in 6 months' time. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spirax Group plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Spirax Group plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.